Post-analysis of the LIVE trial (clinicaltrials.gov identifier: NCT01472640), which evaluated the effect of glucagon-like peptide-1 analog liraglutide on HF in T2D patients [19], found reduced 9-year mortality in patients with low plasma BHB (<0.059 mM) [20]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.